Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease

• DOI: 10.1111/apt.16927
• Publication Date: 2022-04-26T04:54:05Z
• Authors: Viktoria Bergqvist; Johanna Holmgren; Daniel Klintman; Jan Marsal
• Keywords: Vedolizumab; Discontinuation; Faecal calprotectin; Subcutaneous injection

Summary Background and Aims Vedolizumab is a gut‐selective treatment approved for Crohn’s disease (CD) ulcerative colitis (UC). Recently, subcutaneous formulation of vedolizumab was approved. The aims this study were to evaluate efficacy, safety, pharmacokinetics, patient experience costs following switch from intravenous treatment. Methods Patients switched maintenance followed prospectively 6 months subgroup 12 months. primary endpoint change in faecal calprotectin levels. Furthermore, we evaluated clinical activity, remission rates, plasma CRP, drug persistence, adverse events, local injection reactions, serum concentrations, satisfaction, quality‐of‐life costs. Results Eighty‐nine patients included (48 CD; 41 UC). Faecal decreased significantly CD but not UC. Clinical indices, CRP levels scores remained unchanged. that had been on standard compared optimised IV dosing displayed similar outcomes SC dosing. Drug persistence at 95.5% 88.5%, respectively. Frequencies events before after the switch. No serious occurred. Transient severe reactions experienced by 1.2% patients. Median trough 2.3 times higher Patient satisfaction generally high. Annualised reduced 15% Conclusions could be done with preserved therapeutic effectiveness, high low discontinuation rate, cost.